137 related articles for article (PubMed ID: 26113530)
1. Toward optimizing pomalidomide therapy in MM patients.
Podar K
Blood; 2015 Jun; 125(26):3968-9. PubMed ID: 26113530
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
Sehgal K; Das R; Zhang L; Verma R; Deng Y; Kocoglu M; Vasquez J; Koduru S; Ren Y; Wang M; Couto S; Breider M; Hansel D; Seropian S; Cooper D; Thakurta A; Yao X; Dhodapkar KM; Dhodapkar MV
Blood; 2015 Jun; 125(26):4042-51. PubMed ID: 25869284
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
Mark TM; Coleman M; Niesvizky R
Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
[TBL] [Abstract][Full Text] [Related]
4. Pomalidomide for patients with multiple myeloma.
Gras J
Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
[TBL] [Abstract][Full Text] [Related]
5. Pomalidomide: when expectations are understated.
Di Raimondo F; Conticello C
Future Oncol; 2017 Feb; 13(5s):1-2. PubMed ID: 28116940
[No Abstract] [Full Text] [Related]
6. Pooled analysis of pomalidomide for treating patients with multiple myeloma.
Sun JJ; Zhang C; Zhou J; Yang HL
Asian Pac J Cancer Prev; 2015; 16(8):3163-6. PubMed ID: 25921115
[TBL] [Abstract][Full Text] [Related]
7. Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
Leotta S; Pirosa MC; Markovic U; Scalise L; Bulla A; Sapienza G; Di Giorgio MA; Martino EA; Curto Pelle A; Leotta V; Milone G; Cupri A; Vaddinelli D; Villari L; Conticello C; Milone G
Chemotherapy; 2019; 64(2):110-114. PubMed ID: 31533095
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.
Baertsch MA; Hundemer M; Hillengass J; Goldschmidt H; Raab MS
Hematol Oncol; 2018 Feb; 36(1):258-261. PubMed ID: 28840598
[TBL] [Abstract][Full Text] [Related]
9. Pomalidomide-based therapy for extramedullary multiple myeloma.
Li Y; Ji J; Lu H; Li J; Qu X
Hematology; 2022 Dec; 27(1):88-94. PubMed ID: 35068387
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
Sriskandarajah P; Pawlyn C; Mohammed K; Dearden CE; Davies FE; Morgan GJ; Boyd KD; Kaiser MF
Leuk Lymphoma; 2017 Feb; 58(2):494-497. PubMed ID: 27439571
[No Abstract] [Full Text] [Related]
11. Pomalidomide in the management of relapsed multiple myeloma.
Touzeau C; Moreau P
Future Oncol; 2016 Sep; 12(17):1975-83. PubMed ID: 27283457
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of pomalidomide in a multiple myeloma patient requiring hemodialysis].
Kida M; Hirao M; Iizuka H; Hangaishi A; Usuki K
Rinsho Ketsueki; 2016; 57(11):2339-2344. PubMed ID: 27941283
[TBL] [Abstract][Full Text] [Related]
13. Recent studies on the thalidomide and its derivatives.
Łączkowski KZ; Baranowska-Łączkowska A
Future Med Chem; 2018 Sep; 10(18):2133-2136. PubMed ID: 30088422
[No Abstract] [Full Text] [Related]
14. Impact of pomalidomide therapy in multiple myeloma: a recent survey.
Kumar A; Porwal M; Verma A; Mishra AK
J Chemother; 2014 Dec; 26(6):321-7. PubMed ID: 25004945
[TBL] [Abstract][Full Text] [Related]
15. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
16. [Pomalidomide].
Nihon Rinsho; 2016 Jul; 74 Suppl 5():330-4. PubMed ID: 30615392
[No Abstract] [Full Text] [Related]
17. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
[TBL] [Abstract][Full Text] [Related]
19. Pomalidomide. A last-line treatment option for multiple myeloma.
Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]